ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Clinical Trials

3 recruiting

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Trials at a Glance

12 actively recruiting trials for allogeneic hematopoietic stem cell transplantation are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Not Applicable with 3 trials, with the heaviest enrollment activity in Shanghai, New York, and Columbus. Lead sponsors running allogeneic hematopoietic stem cell transplantation studies include Chinese PLA General Hospital, First Affiliated Hospital of Zhejiang University, and Assistance Publique - Hôpitaux de Paris.

Browse allogeneic hematopoietic stem cell transplantation trials by phase

Treatments under study

About ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Clinical Trials

Looking for clinical trials for ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Not Applicable

Nutrition OUtReach In Systems of Healthcare

CAR-T Cell TherapyALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONFood Insecurity+1 more
University of Kansas Medical Center210 enrolled4 locationsNCT06802406
Recruiting
Early Phase 1

Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT

Allogeneic Hematopoietic Stem Cell Transplantation RecipientAdenovirusCytomegalovirus+2 more
Sumithira Vasu20 enrolled2 locationsNCT03665675
Recruiting

Early Detection of Infectious and Noninfectious Lung Diseases Following Allogeneic Hematopoietic Stem Cell Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
National Heart, Lung, and Blood Institute (NHLBI)40 enrolled1 locationNCT06093867
Recruiting
Not Applicable

Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation

Hematologic DisordersPatients With Hematologic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation
The General Hospital of Western Theater Command45 enrolled1 locationNCT07483385
Recruiting
Phase 4

Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Chinese PLA General Hospital200 enrolled1 locationNCT07101588
Recruiting
Phase 3

Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial

VenentoclaxALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONMyeloid Malignancies+3 more
First Affiliated Hospital of Zhejiang University186 enrolled18 locationsNCT07396480
Recruiting
Not Applicable

Prehabilitation for Patients Diagnosed With Blood Cancer and Treated With Al-logeneic Hematopoietic Stem Cell Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation Recipient
Rigshospitalet, Denmark110 enrolled1 locationNCT07341698
Recruiting
Phase 1

Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics

Myelodysplastic Syndrome (MDS)Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)Acute Myeloid Leukaemia (AML)
medac GmbH36 enrolled4 locationsNCT05534620
Recruiting
Phase 2

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Acute Lymphoblastic LeukemiaAcute LeukemiaMyeloproliferative Neoplasm+14 more
Fred Hutchinson Cancer Center68 enrolled10 locationsNCT03779854
Recruiting
Phase 2

Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

RelapseT-cell Acute Lymphoblastic LeukemiaALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine59 enrolled1 locationNCT06686108
Recruiting

Pharmacokinetics of Posaconazole in Allogeneic Transplant Patients With Mucositis

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Universitaire Ziekenhuizen KU Leuven55 enrolled1 locationNCT01420562
Recruiting
Phase 2

Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia or in Relapse After Immunosuppression

Refractory Idiopathic Aplastic AnemiaHaploidentical Allogeneic Hematopoietic Stem Cell Transplantation
Assistance Publique - Hôpitaux de Paris31 enrolled35 locationsNCT05126849